Biotechnology company Sareum Holdings plc (AIM: SAR) announced on Monday that it has completed dosing in the Phase 2-enabling toxicology programme for SDC-1801, its selective oral TYK2/JAK1 inhibitor being developed for autoimmune diseases, initially targeting psoriasis.

Following the programme's restart in February 2026, Sareum said the dosing phase was completed in line with expectations. The company is now analysing data and progressing chemistry, manufacturing and controls and formulation activities.

Sareum expects to complete the full Phase 2-enabling regulatory package by the fourth quarter of 2026 using existing cash resources.